Endocyte Cancer Drug Is Prize Worth Top Premium: Real M&A

Now that Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.